The Question
You have probably heard that your body contains ten times more bacteria than human cells. It is a great line. It is also wrong. When scientists Ron Sender, Shai Fuchs, and Ron Milo actually did the arithmetic in 2016, the real ratio turned out to be far more modest — and far stranger for being true. A typical adult carries about 38 trillion bacterial cells and about 30 trillion human cells. Not ten to one. Roughly one to one, tipped just slightly toward the bacteria.
Sit with that honestly stated fact. By the number of living cells, you are a near-even partnership between your own tissue and a vast crowd of microbes — most of them packed into your gut. For most of medical history, doctors treated those microbes as either irrelevant or as germs to be killed. Now researchers are asking a different question: if half of you is microbial, and that half talks constantly to your immune system, your digestion, and your brain, should medicine start treating the microbes as part of the patient? The evidence increasingly says yes.
What the Evidence Shows
The strongest proof that the microbiome is medicine, not mysticism, comes from a nasty infection called C. difficile. It strikes when antibiotics wipe out the gut's normal bacteria and one aggressive species takes over, causing severe diarrhoea that can kill; the FDA says it is linked to 15,000 to 30,000 deaths a year in the United States. The fix sounds crude and works well: a faecal microbiota transplant, transferring screened stool from a healthy donor to restock the patient's gut. In November 2022 the FDA approved Rebyota, the first faecal microbiota product, and in April 2023 Vowst, the first one taken as a pill, both to prevent the infection from coming back. That is the honest headline: for one disease, resetting the microbiome is now an approved treatment.
Beyond that solid ground, the science is promising but younger. The gut community has been repeatedly linked to how well the immune system works, to inflammatory bowel conditions, to how patients respond to certain cancer drugs, and — through what researchers call the gut-brain axis, the two-way chemical conversation between the intestines and the nervous system — even to mood and anxiety. It is crucial to be precise here: many of these are associations and early trials, not settled cures. The microbiome is not yet a magic dial for every illness, and honest scientists say so.
"Today's approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection."
— Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, April 2023Falling cost is helping. Sequencing the DNA of an entire microbial community — reading which species live in a gut and in what proportions — has become much cheaper, as human genome sequencing did. But a cheap test is only useful if doctors know what to do with the result, and for most conditions there is not yet a validated link between a given microbiome profile and a treatment that works. That is why direct-to-consumer gut tests have spread faster than their clinical use.
For a hundred years medicine tried to sterilise the body. Now it is learning to garden it instead.
Why This Is Happening
One clear success has opened the door. Faecal transplants for C. difficile proved that manipulating the microbiome can treat a real disease. That win gave regulators a template and gave the field credibility. But translating it to other diseases has proved slow, and many microbiome start-ups have struggled to show clear benefits in larger trials.
The reading technology got cheap at the right moment. Understanding the microbiome was impossible while identifying its members cost too much. Plunging DNA-sequencing prices changed that overnight in historical terms. When a diagnostic becomes affordable, it spreads from research labs into ordinary clinics fast — exactly the path that genetic testing took over the past two decades.
The commercial and patient pull is enormous. Conditions tied to the gut — digestive disease, obesity, immune disorders — affect billions and cost health systems fortunes. That creates powerful incentives for drug companies, diagnostics firms, and food makers to invest, while patients frustrated by conditions conventional medicine handles poorly are eager for new options. Demand and money together push a field forward faster than curiosity alone ever could.
What Could Happen
Ordering a gut microbiome analysis becomes as normal as a cholesterol test for some conditions, and approved microbiome therapies expand beyond C. difficile to other digestive and immune diseases by 2035. It is one tool among many, but it sits firmly inside ordinary care.
Microbiome medicine becomes routine for digestive and infection-related conditions, where the evidence is strongest, but the bolder promises — mental health, metabolism, cancer response — stay experimental. Testing is common; sweeping treatment is not. Genuinely useful, but narrower than the enthusiasts predicted.
Unregulated supplements and over-marketed home kits make exaggerated claims, some fail, and the field's reputation suffers. Serious clinical microbiome medicine still advances, but public confidence lags and adoption slows. This is the cautionary path — real, but working against strong scientific and commercial momentum.
What Can We Do
You do not need to wait for 2035 to tend your microbial half — and a little skepticism will protect you while the science matures.
Feed the garden with fibre and variety, not hype. The best-supported way to nurture a healthy gut community is unglamorous: eat a wide range of plants, plenty of fibre, and some fermented foods. This is cheap, safe, and backed by far stronger evidence than most supplements. Start with your plate before you reach for a pill.
Treat antibiotics with respect. Antibiotics save lives, but each course also clears out beneficial microbes — the very disruption that lets infections like C. difficile take hold. Take them when a doctor says you need them, finish the course, and never demand them for viral illnesses like colds, where they do nothing but damage your gut.
Be wary of microbiome kits that promise the world. Direct-to-consumer gut tests vary wildly in quality, and many sell confident "personalised" advice the science cannot yet support. If a product claims to fix your mood, weight, or immunity from a stool sample, treat that as a warning sign. Ask whether a claim comes from a clinical trial or a marketing team.
Raise it with a real doctor, especially for gut disease. If you have a persistent digestive or immune condition, ask your physician what the current, evidence-based microbiome options are. For approved uses like recurrent C. difficile, the treatments are genuine and powerful. A qualified clinician is your best filter between what works today and what is still just a promising headline.